Share “Merck ends development of Januvia-Lipitor...”

Merck ends development of Januvia-Lipitor combo

Associated Press Modified: November 13, 2012 at 1:00 pm •  Published: November 13, 2012

NEW YORK (AP) — Merck & Co. has disclosed that it is ending development of a pill that combines its diabetes drug Januvia with atorvastatin, the main ingredient in Lipitor.

Merck cited unspecified business reasons for ending clinical work on the pill, which was designated MK-0431E. It disclosed the move in a form filed with the Securities and Exchange Commission on Friday.

Januvia is the Whitehouse Station, N.J., company's best-selling drug. In the third quarter revenue from Januvia rose 15 percent to $975 million. That was 50 percent more revenue than its next biggest product, the cholesterol drug Zetia.

Lipitor is marketed by Pfizer Inc. It was the best-selling drug in history, but lost patent protection about a year ago, allowing generic versions to reach the market.

Shares of Merck rose 8 cents to $44.09 in afternoon trading.


  1. 1
    This map shows the biggest music festival in Oklahoma, other states
  2. 2
    Bristol Palin Slams Washington State Initiative to Give Free Birth Control to Minors
  3. 3
    Oregon pot stores sell more than $11 million in first 5 days
  4. 4
    Sigourney Weaver turns 66: Then and now
  5. 5
    Not Sucking in Their Seventies: Rock Lifers Go the Distance
+ show more


× Trending business Article